Astellas Pharma (ALPMY) Stock Forecast & Price Target

Astellas Pharma
Bull Case

Here are some ways that investors could benefit from investing in Astellas Pharma Inc.:

• Astellas Pharma Inc. recently demonstrated strong financial performance by reporting earnings per share of $0.60 for the quarter ended in August 2026, which significantly exceeded the analyst consensus estimate of $0.34, indicating that the company is generating higher profits than expected and potentially signaling improved operational efficiency or stronger demand for its pharmaceutical products.
• The company's revenue for the most recent quarter reached $4.07 billion, surpassing the analyst consensus of $3.45 billion, which suggests that Astellas Pharma Inc. is successfully expanding its market share and that its portfolio of treatments, including XTANDI and PADCEV, is driving robust sales growth that outpaces industry expectations.
• Short interest in Astellas Pharma Inc. shares decreased by 64.5% in September 2026, dropping to 25,074 shares from 70,645 in August, which indicates that investors who were previously betting against the stock are closing their positions, often a sign of increasing confidence in the company's future prospects and reduced bearish pressure on the share price.
• With a current stock price of $14.24 and a P/E ratio of 10.84, Astellas Pharma Inc. appears to be trading at a valuation that is relatively low compared to many of its peers in the pharmaceutical sector, potentially offering investors an opportunity to acquire shares at a price that does not fully reflect the company's recent earnings beats and revenue growth.
• The company maintains a dividend yield of 2.05%, providing a steady stream of income for investors, which is particularly attractive in a market where consistent cash flow from a profitable pharmaceutical manufacturer can serve as a buffer against stock price volatility and enhance total return.